

<b>Reference:</b>	FOI.11485.23
<b>Subject:</b>	Cancer treatment medications
<b>Date of Request:</b>	14 April 2023

**Requested:**

Please may you tell me how many patients were initiated with each drug and indication/form below:

<b>Title</b>	<b>NICE TA Codes</b>
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	TA831
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer	TA693
Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	TA620
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	TA598
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	TA761
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer	TA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	TA654
Acalabrutinib for treating chronic lymphocytic leukaemia	TA689
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	TA798
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	TA862
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies	TA704

Level of Granularity: across all trusts combined.

Data periods:

Monthly from January 2022 to February 2023

Total yearly 2020, 2021 and 2022, for each drug and indication/form above

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare Team, which holds a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records, to establish

the type of cancer diagnosed and therapies used to treat the patients. It is estimated that conducting this search would take longer than the 18 hours 'appropriate limit' as stated within the Freedom of Information Act 2000 (FoIA).

The UHB is therefore applying an exemption under Section 12 of the FoIA, which provides an exemption from a public authority's obligation to comply with a request for information, where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under the FoIA. We therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB, who may be able to help you with your enquiry. The contact details are as follows:-

[FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk) or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.